Dose-dependent Effect of Rosuvastatin on Long-term Clinical Outcomes After PCI
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This study is a prospective, randomized, open-label, single-center trial designed to compare
the 30 month-safety and efficacy between low-dose (5mg/dL) and high-dose (20mg/dL)
rosuvastatin treatment for patients with coronary artery disease after percutaneous coronary
intervention with the newer drug-eluting stent.